Follow
International Journal of Current Microbiology and Applied Sciences (IJCMAS)
IJCMAS is now DOI (CrossRef) registered Research Journal. The DOIs are assigned to all published IJCMAS Articles.
Index Copernicus ICI Journals Master List 2018 - IJCMAS--ICV 2018: 95.39 For more details click here
National Academy of Agricultural Sciences (NAAS) : NAAS Score: *5.38 (2020) [Effective from January 1, 2020]For more details click here

Login as a Reviewer

Indexed in



National Academy of Agricultural Sciences (NAAS)
NAAS Score: *5.38 (2019)
[Effective from January 1, 2019]
For more details click here

ICV 2018: 95.39
Index Copernicus ICI Journals Master List 2017 - IJCMAS--ICV 2018: 95.39
For more details click here

See Guidelines to Authors
Current Issues

Original Research Articles

PRINT ISSN : 2319-7692
Online ISSN : 2319-7706
Issues : 12 per year
Publisher : Excellent Publishers
Email : editorijcmas@gmail.com / submit@ijcmas.com
Editor-in-chief: Dr.M.Prakash
Index Copernicus ICV 2018: 95.39
NAAS RATING 2020: 5.38

Int.J.Curr.Microbiol.App.Sci.2020.9(4): 1344-1355
DOI: https://doi.org/10.20546/ijcmas.2020.904.160


Transforming Growth Factor Beta 1 (TGFβ1) as an Immunological Marker in Breast Cancer Patients
Amr Mohamed El-Sabbagh1*, Wafaa Saad Zaghloul1, Raghda El-sayed Megahedand Nazem Mohammed Shams3
1Department of Medical Microbiology and Immunology, Faculty of Medicine,
Mansoura University, Egypt
2Mansoura Fever Hospital, Ministry of Health, 3Department of general surgery, Faculty of Medicine, Mansoura University, Egypt
*Corresponding author
Abstract:

Breast cancer is one of the most public and fatal malignancy worldwide. One of the main cytokines playing a role in breast cancer progression is TGFb1. In this study we aimed to determine the clinical significance of the serum TGFβ1 levels in breast cancer patients by comparing the levels of TGFβ1 in breast cancer patients and in control females, assessment of the levels of TGFβ1 in diagnosed breast cancer patients before and after treatment and correlating between the levels of TGFβ1 in breast cancer patients with the laboratory and radiological findings. Our study was carried out on 35 breast cancer female cases and 20 females free from breast cancer with matched age as a control group. Higher levels of TGFβ1 are detected among breast cancer females than the control group with statistically significant difference between TGFβ1 after treatment as regarding to metastasis occurrence. This indicates that the circulating TGFβ1 after treatment may be used as a prognostic marker in breast cancer patients. Also, our study shows that there were statistically significant predictors affecting metastasis rate among studied cases when both ER was positive and TGFβ1 after treatment was more than median.


Keywords: Fatal malignancy,Cytokines, TGFβ1 Predictors
Download this article as Download

How to cite this article:

Amr Mohamed El-Sabbagh, Wafaa Saad Zaghloul, Raghda El-sayed Megahed and Nazem Mohammed Shams. 2020. Transforming Growth Factor Beta 1 (TGFβ1) as an Immunological Marker in Breast Cancer Patients.Int.J.Curr.Microbiol.App.Sci. 9(4): 1344-1355. doi: https://doi.org/10.20546/ijcmas.2020.904.160